Back to mobile site

BTIG Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

May 30, 2025 12:12 PM EDT Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $42.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).The analyst comments "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login